Posted on Leave a comment

Bullous Pemphigoid Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | AstraZeneca, AKARI Therapeutics, Regeneron Pharma, Argenx

Bullous Pemphigoid Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | AstraZeneca, AKARI Therapeutics, Regeneron Pharma, Argenx
The Bullous Pemphigoid market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bullous Pemphigoid pipeline products will significantly revolutionize the Bullous Pemphigoid market dynamics.

DelveInsight’s “Bullous Pemphigoid Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Bullous Pemphigoid, historical and forecasted epidemiology as well as the Bullous Pemphigoid market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


The Bullous Pemphigoid market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 


To Know in detail about the Bullous Pemphigoid market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bullous Pemphigoid Market Insights


Bullous Pemphigoid Overview

As per national organization of rare diseases (NORD), bullous pemphigoid (BP) is a rare, autoimmune, chronic skin disorder characterized by blistering, urticarial lesions (hives) and itching. Less commonly these blisters can involve the mucous membranes including the eyes, oral mucosa, oesophagus and genital mucosa. Moreover, it is the most common autoimmune subepidermal blistering disorder, representing 80% of subepidermal immunobullous cases.

BD most commonly affects elderly patients between the ages of 60 to 80 years. It ranges from mildly itchy welts to severe blisters and infection, and may affect a small area of the body or be widespread. It is caused by autoantibodies directed against the hemidesmosomal proteins BP180 and BP230.


Some of the key facts of the Bullous Pemphigoid Market Report: 

  • The Bullous Pemphigoid market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • According to Baigrie and Nookala, BP affects individuals older than 60 years of age. The annual incidence is 6 to 13 new cases per million people in the United States, while it affects 12 to 13 per million in Central Europe. It has an equal incidence in both males and females and has no racial bias
  • As per Kridin and Ludwig (2018), based on health insurance data, the prevalence of BP has been estimated at 259 per million population in Germany, i.e., ~21,000 patients with BP lived in Germany
  • Key Bullous Pemphigoid Companies: AstraZeneca, AKARI Therapeutics, Regeneron Pharmaceuticals, Argenx, and others
  • Key Bullous Pemphigoid Therapies: Benralizumab, Nomacopan, Dupilumab, Efgartigimod, and others
  • The Bullous Pemphigoid epidemiology based on age-specific cases analyzed that Bullous Pemphigoid is more prevalent in older age group (66 to 83 years)


Get a Free sample for the Bullous Pemphigoid Market Report –


Key benefits of the Bullous Pemphigoid Market report:

  1. Bullous Pemphigoid market report covers a descriptive overview and comprehensive insight of the Bullous Pemphigoid Epidemiology and Bullous Pemphigoid market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Bullous Pemphigoid market report provides insights on the current and emerging therapies.
  3. Bullous Pemphigoid market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Bullous Pemphigoid market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Bullous Pemphigoid market.


Download the report to understand which factors are driving Bullous Pemphigoid epidemiology trends @ Bullous Pemphigoid Epidemiological Insights 


Bullous Pemphigoid Market  

The dynamics of the Bullous Pemphigoid market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.  


Bullous Pemphigoid Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.


Bullous Pemphigoid Epidemiology Segmentation:

The Bullous Pemphigoid market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Bullous Pemphigoid
  • Prevalent Cases of Bullous Pemphigoid by severity
  • Gender-specific Prevalence of Bullous Pemphigoid
  • Diagnosed Cases of Episodic and Chronic Bullous Pemphigoid


Bullous Pemphigoid Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bullous Pemphigoid market or expected to get launched during the study period. The analysis covers Bullous Pemphigoid market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Bullous Pemphigoid Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.


To know more about Bullous Pemphigoid treatment, visit @ Bullous Pemphigoid Medications 


Bullous Pemphigoid Therapies and Key Companies

  • Benralizumab: AstraZeneca
  • Nomacopan: AKARI Therapeutics
  • Dupilumab: Regeneron Pharmaceuticals
  • Efgartigimod: Argenx


Bullous Pemphigoid Market Strengths

  • Important progress has been made regarding understanding disease pathology, diagnosis, and treatment effects in Bullous Pemphigoid.
  • Population rates of social anxiety disorder in children and young people have been investigated in several countries.
  • Many therapies are under investigation in various phases of clinical trials.


Scope of the Bullous Pemphigoid Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Bullous Pemphigoid Companies: AstraZeneca, AKARI Therapeutics, Regeneron Pharmaceuticals, Argenx, and others
  • Key Bullous Pemphigoid Therapies: Benralizumab, Nomacopan, Dupilumab, Efgartigimod, and others
  • Bullous Pemphigoid Therapeutic Assessment: Bullous Pemphigoid current marketed and Bullous Pemphigoid emerging therapies
  • Bullous Pemphigoid Market Dynamics:  Bullous Pemphigoid market drivers and Bullous Pemphigoid market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Bullous Pemphigoid Unmet Needs, KOL’s views, Analyst’s views, Bullous Pemphigoid Market Access and Reimbursement 


Bullous Pemphigoid Market Unmet Needs

  • Challenge in recognition of condition
  • Development of novel therapies
  • Limited availability in services
  • Poor disease understanding
  • Development of effective treatment


Table of Contents 

1. Bullous Pemphigoid Market Report Introduction

2. Executive Summary for Bullous Pemphigoid

3. SWOT analysis of Bullous Pemphigoid

4. Bullous Pemphigoid Patient Share (%) Overview at a Glance

5. Bullous Pemphigoid Market Overview at a Glance

6. Bullous Pemphigoid Disease Background and Overview

7. Bullous Pemphigoid Epidemiology and Patient Population

8. Country-Specific Patient Population of Bullous Pemphigoid 

9. Bullous Pemphigoid Current Treatment and Medical Practices

10. Bullous Pemphigoid Unmet Needs

11. Bullous Pemphigoid Emerging Therapies

12. Bullous Pemphigoid Market Outlook

13. Country-Wise Bullous Pemphigoid Market Analysis (2019–2032)

14. Bullous Pemphigoid Market Access and Reimbursement of Therapies

15. Bullous Pemphigoid Market Drivers

16. Bullous Pemphigoid Market Barriers

17.  Bullous Pemphigoid Appendix

18. Bullous Pemphigoid Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight


About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States